Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Operating Expenses (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Operating Expenses for 11 consecutive years, with $19.8 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 31.28% to $19.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $94.8 million through Dec 2025, down 21.89% year-over-year, with the annual reading at $94.8 million for FY2025, 21.89% down from the prior year.
  • Operating Expenses hit $19.8 million in Q4 2025 for Seres Therapeutics, down from $22.8 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $76.9 million in Q2 2023 to a low of -$4.4 million in Q4 2022.
  • Historically, Operating Expenses has averaged $41.7 million across 5 years, with a median of $39.0 million in 2021.
  • Biggest five-year swings in Operating Expenses: plummeted 107.81% in 2022 and later skyrocketed 937.27% in 2023.
  • Year by year, Operating Expenses stood at $56.7 million in 2021, then tumbled by 107.81% to -$4.4 million in 2022, then surged by 937.27% to $37.0 million in 2023, then decreased by 22.12% to $28.8 million in 2024, then crashed by 31.28% to $19.8 million in 2025.
  • Business Quant data shows Operating Expenses for MCRB at $19.8 million in Q4 2025, $22.8 million in Q3 2025, and $24.9 million in Q2 2025.